ARCHIVES

How NCI Plans to Spend the $3 Billion Budget; But First, A Caveat From the Director

This article is from The Cancer Letter archive.

Vol. 25 No. 44 | November 19, 1999

Download PDF Visit The Full Archive

Related Articles

Tasigna Wins New Indication For CML; Jevtana Approved For Prostate Cancer

June 18, 2010

Trial Data: No Benefit In Adding Perifosine to Capecitabine

June 29, 2012

Timeline Pinpoints the Role of Cancer Scandal In a Progression Leading to Perry’s Indictment

September 5, 2014

Studies Question PSA Screening: PLCO Trial Finds No Survival Advantage, European Trial Finds Benefit At High Cost

March 20, 2009

Galeterone Shows Potential In CRPC AR Variants, Study Says

November 28, 2014

Program Committee Lists 10 Papers At AACR Meeting

July 19, 1985